GLP-1 drugsReview

EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy

Figure 1 from Journal of Hepatology — Figure 1European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu et al.

Journal of Hepatology

The paper

Frank Tacke, Paul Horn, Vincent Wai Sun Wong,

Vlad Ratziu, Elisabetta Bugianesi, Sven Francque, Shira Zelber‐Sagi, Cyrielle Caussy, Michael Roden, Amalia Gastaldelli, Andreea Ciudin,

Barbara Mcgowan

Journal of Hepatology · 29 Sep 2026

doi.org/10.1016/j.jhep.2026.08.028 PubMed 42805503

Nutrient deficiencies raise metabolic risk in obesity
Nutrients · 4 Oct 2026
NMR metabolomics improves prediction of cardiometabolic diseases
medRxiv · 4 Oct 2026
GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026